Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
- Did Cloud Seeding Unleash a Deluge in Dubai?
- Scientists Identify Gut Bacteria and Metabolites that Lower Diabetes Risk
- OpenAI’s Model Matches Doctors in Assessing Eye Conditions
- UK: A Smoke-Free Generation by Banning Sales to Those Born After 2009
- Deadly Mutation: A New Monkeypox Variant Emerges in the DRC
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall.
Moderna hopes to launch a vaccine against Covid-19, influenza and respiratory syncytial virus (a common respiratory virus) as early as fall 2023, Chief Executive Stephane Bancel said on Monday. The three-in-one vaccine booster shot.
Moderna’s chief executive, Stéphane Bancel, said the company’s goal is to have the compound vaccine available in multiple countries in the next 18 months or so.
In addition to immunizing people against Covid-19 and the flu virus, the vaccine will target respiratory syncytial virus (RSV), a common virus that often causes cold-like symptoms.
“Our goal is to develop a booster shot with only one dose per year. If people don’t want to get 2 or 3 doses of vaccine every winter, they just want to get one dose, so there will be no compliance issues.” Bancel in the world Speaking at a virtual roundtable of the World Economic Forum.
In the best-case scenario, the compound vaccine would be available in some countries by the fall of 2023, Bancel said.
He said that the RSV project is in the third phase of trials, which is the final stage of human testing; while the influenza project is in the second phase of trials and is expected to enter the third phase of trials in the second quarter of this year.
Bancel also said that Moderna’s vaccine candidate for the mutated virus Omicron has basically been developed and is about to enter the clinical stage.
The company expects to share data with regulators around March, he added.
Like Pfizer and its partner BioNTech, Moderna has developed a Covid-19 vaccine using advanced messenger RNA (mRNA) technology that differs from traditional vaccines, and has achieved impressive results. The company and its shareholders hope to see more growth from mRNA technology in the future.
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
